{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:16:25Z","timestamp":1727842585886},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00105-024-05407-7","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:02:45Z","timestamp":1725008565000},"page":"791-797","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phosphodiesterase-4-Inhibitoren in der Dermatologie","Phosphodiesterase\u00a04 inhibitors in dermatology"],"prefix":"10.1007","volume":"75","author":[{"given":"Morna F.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Albuscheit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir S.","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"4","key":"5407_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice\u00a0DH, Ke\u00a0H, Ahmad\u00a0F, Wang\u00a0Y, Chung\u00a0J, Manganiello\u00a0VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290\u2013314","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5407_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","volume":"39","author":"CH Serezani","year":"2008","unstructured":"Serezani\u00a0CH, Ballinger\u00a0MN, Aronoff\u00a0DM, Peters-Golden\u00a0M (2008) Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39(2):127\u2013132","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5407_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li\u00a0H, Zuo\u00a0J, Tang\u00a0W (2018) Phosphodiesterase\u20114 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol 9:1048","journal-title":"Front Pharmacol"},{"issue":"12","key":"5407_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer\u00a0P (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83(12):1583\u20131590","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"5407_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","volume":"12","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi\u00a0A, Caposiena\u00a0D, Garofalo\u00a0V, Cannizzaro\u00a0MV, Chimenti\u00a0S, Saraceno\u00a0R (2016) A\u00a0new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Rev Clin Immunol 12(3):237\u2013249","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"5407_CR6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jid.2023.09.272","volume":"144","author":"K Takahashi","year":"2024","unstructured":"Takahashi\u00a0K, Miyake\u00a0K, Ito\u00a0J, Shimamura\u00a0H, Suenaga\u00a0T, Karasuyama\u00a0H et\u00a0al (2024) Topical Application of a\u00a0PDE4 Inhibitor Ameliorates Atopic Dermatitis through Inhibition of Basophil IL\u20114 Production. J\u00a0Invest Dermatol 144(5):1048\u20131057","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5407_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.123.001609","volume":"386","author":"H Hiyama","year":"2023","unstructured":"Hiyama\u00a0H, Arichika\u00a0N, Okada\u00a0M, Koyama\u00a0N, Tahara\u00a0T, Haruta\u00a0J (2023) Pharmacological Profile of Difamilast, a\u00a0Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis. J\u00a0Pharmacol Exp Ther 386(1):45\u201355","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"5407_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer\u00a0PH, Truzzi\u00a0F, Parton\u00a0A, Wu\u00a0L, Kosek\u00a0J, Zhang\u00a0LH et\u00a0al (2016) Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal 28(7):753\u2013763","journal-title":"Cell Signal"},{"issue":"4","key":"5407_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1527-3458.2001.tb00206.x","volume":"7","author":"J Zhu","year":"2001","unstructured":"Zhu\u00a0J, Mix\u00a0E, Winblad\u00a0B (2001) The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev 7(4):387\u2013398","journal-title":"CNS Drug Rev"},{"issue":"4","key":"5407_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","volume":"68","author":"AW Armstrong","year":"2013","unstructured":"Armstrong\u00a0AW, Harskamp\u00a0CT, Armstrong\u00a0EJ (2013) Psoriasis and metabolic syndrome: a\u00a0systematic review and meta-analysis of observational studies. J\u00a0Am Acad Dermatol 68(4):654\u2013662","journal-title":"J Am Acad Dermatol"},{"issue":"10281","key":"5407_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths\u00a0CEM, Armstrong\u00a0AW, Gudjonsson\u00a0JE, Barker\u00a0J (2021) Psoriasis. Lancet 397(10281):1301\u20131315","journal-title":"Lancet"},{"issue":"6","key":"5407_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu\u00a0JJ, Kavanaugh\u00a0A, Lebwohl\u00a0MG, Gniadecki\u00a0R, Merola\u00a0JF (2022) Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J\u00a0Eur Acad Dermatol Venereol 36(6):797\u2013806","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5407_CR13","unstructured":"013\u2013001l_S3_Therapie-Psoriasis-vulgaris_2021-07-verlaengert.pdf (awmf.org). Stand Juni 2024"},{"key":"5407_CR14","doi-asserted-by":"crossref","unstructured":"Crowley EL, Gooderham MJ (2023) Phosphodiesterase\u20114 Inhibition in the Management of Psoriasis. Pharmaceutics 16(1)","DOI":"10.3390\/pharmaceutics16010023"},{"key":"5407_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.acc.2020.04.004","volume":"100","author":"CC de Alcantara","year":"2021","unstructured":"de Alcantara\u00a0CC, Reiche\u00a0EMV, Simao\u00a0ANC (2021) Cytokines in psoriasis. Adv Clin Chem 100:171\u2013204","journal-title":"Adv Clin Chem"},{"issue":"6","key":"5407_CR16","first-page":"36","volume":"9","author":"BI Ferreira","year":"2016","unstructured":"Ferreira\u00a0BI, Abreu\u00a0JL, Reis\u00a0JP, Figueiredo\u00a0AM (2016) Psoriasis and Associated Psychiatric Disorders: A\u00a0Systematic Review on Etiopathogenesis and Clinical Correlation. J\u00a0Clin Aesthet Dermatol 9(6):36\u201343","journal-title":"J Clin Aesthet Dermatol"},{"key":"5407_CR17","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/apremilast-accord. Zugegriffen: 06.2024"},{"key":"5407_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/ITT.S40199","volume":"3","author":"A Cauli","year":"2014","unstructured":"Cauli\u00a0A, Porru\u00a0G, Piga\u00a0M, Vacca\u00a0A, Dessole\u00a0G, Mathieu\u00a0A (2014) Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther 3:91\u201396","journal-title":"Immunotargets Ther"},{"issue":"4","key":"5407_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer\u00a0PH, Parton\u00a0A, Gandhi\u00a0AK, Capone\u00a0L, Adams\u00a0M, Wu\u00a0L et\u00a0al (2010) Apremilast, a\u00a0cAMP phosphodiesterase\u20114 inhibitor, demonstrates anti-inflammatory activity in vitro and in a\u00a0model of psoriasis. Br J Pharmacol 159(4):842\u2013855","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5407_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp\u00a0K, Reich\u00a0K, Leonardi\u00a0CL, Kircik\u00a0L, Chimenti\u00a0S, Langley\u00a0RG et\u00a0al (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a\u00a0phase\u00a0III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J\u00a0Am Acad Dermatol 73(1):37\u201349","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5407_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul\u00a0C, Cather\u00a0J, Gooderham\u00a0M, Poulin\u00a0Y, Mrowietz\u00a0U, Ferrandiz\u00a0C et\u00a0al (2015) Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52\u00a0weeks: a\u00a0phase\u00a0III, randomized controlled trial (ESTEEM 2). Br J Dermatol 173(6):1387\u20131399","journal-title":"Br J Dermatol"},{"issue":"3","key":"5407_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich\u00a0K, Gooderham\u00a0M, Green\u00a0L, Bewley\u00a0A, Zhang\u00a0Z, Khanskaya\u00a0I et\u00a0al (2017) The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a\u00a0phase\u00a0IIIb, randomized, placebo-controlled trial (LIBERATE). J\u00a0Eur Acad Dermatol Venereol 31(3):507\u2013517","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"5407_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jaad.2023.11.068","volume":"90","author":"L Fiorillo","year":"2024","unstructured":"Fiorillo\u00a0L, Becker\u00a0E, de Lucas\u00a0R, Belloni-Fortina\u00a0A, Armesto\u00a0S, Elewski\u00a0B et\u00a0al (2024) Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a\u00a0randomized controlled trial. J\u00a0Am Acad Dermatol 90(6):1232\u20131239","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5407_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2340\/00015555-2360","volume":"96","author":"JM Sobell","year":"2016","unstructured":"Sobell\u00a0JM, Foley\u00a0P, Toth\u00a0D, Mrowietz\u00a0U, Girolomoni\u00a0G, Goncalves\u00a0J et\u00a0al (2016) Effects of Apremilast on Pruritus and Skin Discomfort\/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. Acta Derm Venereol 96(4):514\u2013520","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"5407_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1310\/hpj4908-752","volume":"49","author":"DJ Cada","year":"2014","unstructured":"Cada\u00a0DJ, Ingram\u00a0K, Baker\u00a0DE (2014) Apremilast. Hosp Pharm 49(8):752\u2013762","journal-title":"Hosp Pharm"},{"issue":"5","key":"5407_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","volume":"29","author":"M Gooderham","year":"2015","unstructured":"Gooderham\u00a0M, Papp\u00a0K (2015) Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs 29(5):327\u2013339","journal-title":"BioDrugs"},{"key":"5407_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156(3","author":"AW Armstrong","year":"2020","unstructured":"Armstrong\u00a0AW, Puig\u00a0L, Joshi\u00a0A, Skup\u00a0M, Williams\u00a0D, Li\u00a0J et\u00a0al (2020) Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A\u00a0Meta-analysis. JAMA Dermatol 156(3:258\u2013269","journal-title":"JAMA Dermatol"},{"key":"5407_CR28","unstructured":"Gold SL, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ et\u00a0al (2024) Long-term safety and effectiveness of roflumilast cream 0.3\u202f% in adults with chronic plaque psoriasis: A\u00a052-week, phase\u00a02, open-label trial. J\u00a0Am Acad Dermatol"},{"key":"5407_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/PTT.S303634","volume":"11","author":"M Milakovic","year":"2021","unstructured":"Milakovic\u00a0M, Gooderham\u00a0MJ (2021) Phosphodiesterase\u20114 Inhibition in Psoriasis. Psoriasis 11:21\u201329","journal-title":"Psoriasis"},{"issue":"3","key":"5407_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.116.232819","volume":"358","author":"C Dong","year":"2016","unstructured":"Dong\u00a0C, Virtucio\u00a0C, Zemska\u00a0O, Baltazar\u00a0G, Zhou\u00a0Y, Baia\u00a0D et\u00a0al (2016) Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes. J\u00a0Pharmacol Exp Ther 358(3):413\u2013422","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"5407_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"SL Gold","year":"2022","unstructured":"Gold\u00a0SL, Papp\u00a0K, Pariser\u00a0D, Green\u00a0L, Bhatia\u00a0N, Sofen\u00a0H et\u00a0al (2022) Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a\u00a0phase\u00a03, multicenter, randomized, double-blind, placebo-controlled trial. J\u00a0Am Acad Dermatol 86(1):77\u201385","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5407_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","volume":"82","author":"PW Hashim","year":"2020","unstructured":"Hashim\u00a0PW, Chima\u00a0M, Kim\u00a0HJ, Bares\u00a0J, Yao\u00a0CJ, Singer\u00a0G et\u00a0al (2020) Crisaborole 2\u202f% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A\u00a0double-blind, randomized, vehicle-controlled trial. J\u00a0Am Acad Dermatol 82(2):360\u2013365","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5407_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/09546634.2018.1480747","volume":"30","author":"EB Lee","year":"2019","unstructured":"Lee\u00a0EB, Lebwohl\u00a0MG, Wu\u00a0JJ (2019) Treatment of psoriasis with crisaborole. J\u00a0Dermatolog Treat 30(2):156\u2013157","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"5407_CR34","doi-asserted-by":"publisher","first-page":"e15424","DOI":"10.1111\/dth.15424","volume":"35","author":"Y Liu","year":"2022","unstructured":"Liu\u00a0Y, Li\u00a0W (2022) Successful treatment with crisaborole for facial lesions refractory to adalimumab in a\u00a0man with psoriasis: A\u00a0case report. Dermatol Ther 35(5):e15424","journal-title":"Dermatol Ther"},{"issue":"9","key":"5407_CR35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamadermatol.2018.2397","volume":"154","author":"AB Robbins","year":"2018","unstructured":"Robbins\u00a0AB, Gor\u00a0A, Bui\u00a0MR (2018) Topical Crisaborole\u2011A Potential Treatment for Recalcitrant Palmoplantar Psoriasis. JAMA Dermatol 154(9):1096\u20131097","journal-title":"JAMA Dermatol"},{"issue":"10023","key":"5407_CR36","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger\u00a0S, Novak\u00a0N (2016) Atopic dermatitis. Lancet 387(10023):1109\u20131122","journal-title":"Lancet"},{"issue":"5","key":"5407_CR37","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris\u00a0P, Jeffery\u00a0J, Del Duca\u00a0E, Guttman-Yassky\u00a0E (2023) The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 20(5):448\u2013474","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"5407_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40264-015-0287-7","volume":"38","author":"L Barnes","year":"2015","unstructured":"Barnes\u00a0L, Kaya\u00a0G, Rollason\u00a0V (2015) Topical corticosteroid-induced skin atrophy: a\u00a0comprehensive review. Drug Saf 38(5):493\u2013509","journal-title":"Drug Saf"},{"issue":"1","key":"5407_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy\u00a0N, Chu\u00a0A, Wong\u00a0M, Srivastava\u00a0A, Ceccacci\u00a0R, Lin\u00a0C et\u00a0al (2023) Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a\u00a0systematic review and meta-analysis. Lancet Child Adolesc Health 7(1):13\u201325","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"5407_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2249.1995.tb03123.x","volume":"101","author":"AR Moore","year":"1995","unstructured":"Moore\u00a0AR, Willoughby\u00a0DA (1995) The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 101(3):387\u2013389","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"5407_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13808","volume":"28","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky\u00a0E, Hanifin\u00a0JM, Boguniewicz\u00a0M, Wollenberg\u00a0A, Bissonnette\u00a0R, Purohit\u00a0V et\u00a0al (2019) The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol 28(1):3\u201310","journal-title":"Exp Dermatol"},{"issue":"1","key":"5407_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/archderm.1977.01640010109018","volume":"113","author":"RJ Kaplan","year":"1977","unstructured":"Kaplan\u00a0RJ, Daman\u00a0L, Rosenberg\u00a0EW, Feigenbaum\u00a0S (1977) Treatment of atopic dermatitis with topically applied caffeine\u2014a follow-up report. Arch Dermatol 113(1):107","journal-title":"Arch Dermatol"},{"issue":"5","key":"5407_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/0091-6749(83)90467-0","volume":"71","author":"JM Butler","year":"1983","unstructured":"Butler\u00a0JM, Chan\u00a0SC, Stevens\u00a0S, Hanifin\u00a0JM (1983) Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J\u00a0Allergy Clin Immunol 71(5):490\u2013497","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5407_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1523-1747.ep12272486","volume":"84","author":"KD Cooper","year":"1985","unstructured":"Cooper\u00a0KD, Kang\u00a0K, Chan\u00a0SC, Hanifin\u00a0JM (1985) Phosphodiesterase inhibition by Ro 20\u20131724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J\u00a0Invest Dermatol 84(6):477\u2013482","journal-title":"J Invest Dermatol"},{"issue":"1","key":"5407_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","volume":"107","author":"JM Hanifin","year":"1996","unstructured":"Hanifin\u00a0JM, Chan\u00a0SC, Cheng\u00a0JB, Tofte\u00a0SJ, Henderson\u00a0WR Jr., Kirby\u00a0DS et\u00a0al (1996) Type\u00a04 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J\u00a0Invest Dermatol 107(1):51\u201356","journal-title":"J Invest Dermatol"},{"issue":"8","key":"5407_CR46","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2217\/imt-2016-0023","volume":"8","author":"LT Zane","year":"2016","unstructured":"Zane\u00a0LT, Chanda\u00a0S, Jarnagin\u00a0K, Nelson\u00a0DB, Spelman\u00a0L, Gold\u00a0LS (2016) Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 8(8):853\u2013866","journal-title":"Immunotherapy"},{"issue":"5","key":"5407_CR47","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s13555-021-00584-y","volume":"11","author":"B Geng","year":"2021","unstructured":"Geng\u00a0B, Hebert\u00a0AA, Takiya\u00a0L, Miller\u00a0L, Werth\u00a0JL, Zang\u00a0C et\u00a0al (2021) Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged \u3009\/= 2 Years with Mild-to-Moderate Atopic Dermatitis. Dermatol Ther (Heidelb) 11(5):1667\u20131678","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"5407_CR48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller\u00a0AS, Tom\u00a0WL, Lebwohl\u00a0MG, Blumenthal\u00a0RL, Boguniewicz\u00a0M, Call\u00a0RS et\u00a0al (2016) Efficacy and safety of crisaborole ointment, a\u00a0novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J\u00a0Am Acad Dermatol 75(3):494\u2013503","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"5407_CR49","first-page":"1394","volume":"14","author":"SLF Gold","year":"2015","unstructured":"Gold\u00a0SLF, Spelman\u00a0L, Spellman\u00a0MC, Hughes\u00a0MH, Zane\u00a0LT (2015) A\u00a0Phase\u00a02, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5\u202f% and 2\u202f% in Adolescents With Mild to Moderate Atopic Dermatitis. J\u00a0Drugs Dermatol 14(12):1394\u20131399","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"5407_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","volume":"24","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield\u00a0LF, Gower\u00a0RG, Xu\u00a0J, Alam\u00a0MS, Su\u00a0JC, Myers\u00a0DE et\u00a0al (2023) Once-Daily Crisaborole Ointment, 2\u202f%, as a\u00a0Long-Term Maintenance Treatment in Patients Aged \u3009\/= 3 Months with Mild-to-Moderate Atopic Dermatitis: A\u00a052-Week Clinical Study. Am J Clin Dermatol 24(4):623\u2013635","journal-title":"Am J Clin Dermatol"},{"key":"5407_CR51","unstructured":"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220131154270\/dec_154270_de.pdf. Zugegriffen: 06.2024"},{"key":"5407_CR52","unstructured":"https:\/\/register.awmf.org\/assets\/guidelines\/007-101l_S2k_Aphthen_aphthoide-L%C3%A4sionen_2023-06_02.pdf. Zugegriffen: 06.2024"},{"key":"5407_CR53","volume-title":"Behcet Disease. StatPearls","author":"A Adil","year":"2024","unstructured":"Adil\u00a0A, Goyal\u00a0A, Quint\u00a0JM (2024) Behcet Disease. StatPearls. Treasure Island"},{"issue":"4","key":"5407_CR54","first-page":"433","volume":"148","author":"DG James","year":"1988","unstructured":"James\u00a0DG (1988) Silk route disease\u2019 (Behcet\u2019s disease). West J Med 148(4):433\u2013437","journal-title":"West J Med"},{"issue":"9","key":"5407_CR55","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/art.42486","volume":"75","author":"A Le Joncour","year":"2023","unstructured":"Le Joncour\u00a0A, Regnier\u00a0P, Maciejewski-Duval\u00a0A, Charles\u00a0E, Barete\u00a0S, Fouret\u00a0P et\u00a0al (2023) Reduction of Neutrophil Activation by Phosphodiesterase 4 Blockade in Behcet\u2019s Disease. Arthritis Rheumatol 75(9):1628\u20131637","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"5407_CR56","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi\u00a0G, Melikoglu\u00a0M, Tunc\u00a0R, Korkmaz\u00a0C, Turgut Ozturk\u00a0B, Mat\u00a0C et\u00a0al (2015) Apremilast for Behcet\u2019s syndrome\u2014a phase\u00a02, placebo-controlled study. N\u00a0Engl J Med 372(16):1510\u20131518","journal-title":"N Engl J Med"},{"key":"5407_CR57","doi-asserted-by":"publisher","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","volume":"11","author":"M Vieira","year":"2020","unstructured":"Vieira\u00a0M, Buffier\u00a0S, Vautier\u00a0M, Le Joncour\u00a0A, Jamilloux\u00a0Y, Gerfaud-Valentin\u00a0M et\u00a0al (2020) Apremilast in Refractory Behcet\u2019s Syndrome: A\u00a0Multicenter Observational Study. Front Immunol 11:626792","journal-title":"Front Immunol"},{"key":"5407_CR58","doi-asserted-by":"crossref","unstructured":"Hatemi G, Mahr A, Takeno M, Kim D, Melikoglu M, Cheng S et\u00a0al (2022) Impact of apremilast on quality of life in Behcet\u2019s syndrome: analysis of the phase\u00a03 RELIEF study. RMD Open 8(2)","DOI":"10.1136\/rmdopen-2022-002235"},{"key":"5407_CR59","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2147\/CCID.S390591","volume":"15","author":"V Viswanath","year":"2022","unstructured":"Viswanath\u00a0V, Joshi\u00a0P, Dhakne\u00a0M, Dhoot\u00a0D, Mahadkar\u00a0N, Barkate\u00a0H (2022) Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus. Clin Cosmet Investig Dermatol 15:2593\u20132600","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"5407_CR60","first-page":"343","volume":"20","author":"L Perschy","year":"2022","unstructured":"Perschy\u00a0L, Anzengruber\u00a0F, Rappersberger\u00a0K, Itzlinger-Monshi\u00a0B, Aichelburg\u00a0MC, Graf\u00a0V et\u00a0al (2022) Apremilast bei oralem Lichen planus \u2013 eine multizentrische, retrospektive Studie. J\u00a0Dtsch Dermatol Ges 20(3):343\u2013348","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"5407_CR61","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/ar3041","volume":"12","author":"FE McCann","year":"2010","unstructured":"McCann\u00a0FE, Palfreeman\u00a0AC, Andrews\u00a0M, Perocheau\u00a0DP, Inglis\u00a0JJ, Schafer\u00a0P et\u00a0al (2010) Apremilast, a\u00a0novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 12(3):R107","journal-title":"Arthritis Res Ther"},{"key":"5407_CR62","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fimmu.2018.01662","volume":"9","author":"W Chen","year":"2018","unstructured":"Chen\u00a0W, Wang\u00a0J, Xu\u00a0Z, Huang\u00a0F, Qian\u00a0W, Ma\u00a0J et\u00a0al (2018) Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4(+)Foxp3(+) Regulatory T Cells Differentiation. Front Immunol 9:1662","journal-title":"Front Immunol"},{"issue":"1","key":"5407_CR63","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00418-008-0420-0","volume":"130","author":"J Waschke","year":"2008","unstructured":"Waschke\u00a0J (2008) The desmosome and pemphigus. Histochem Cell Biol 130(1):21\u201354","journal-title":"Histochem Cell Biol"},{"key":"5407_CR64","doi-asserted-by":"publisher","first-page":"588315","DOI":"10.3389\/fimmu.2020.588315","volume":"11","author":"K Meier","year":"2020","unstructured":"Meier\u00a0K, Holstein\u00a0J, Solimani\u00a0F, Waschke\u00a0J, Ghoreschi\u00a0K (2020) Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris. Front Immunol 11:588315","journal-title":"Front Immunol"},{"issue":"11","key":"5407_CR65","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.4049\/jimmunol.1002675","volume":"185","author":"V Spindler","year":"2010","unstructured":"Spindler\u00a0V, Vielmuth\u00a0F, Schmidt\u00a0E, Rubenstein\u00a0DS, Waschke\u00a0J (2010) Protective endogenous cyclic adenosine 5\u2019-monophosphate signaling triggered by pemphigus autoantibodies. J\u00a0Immunol 185(11):6831\u20136838","journal-title":"J Immunol"},{"issue":"1","key":"5407_CR66","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-022-35741-0","volume":"14","author":"AM Sigmund","year":"2023","unstructured":"Sigmund\u00a0AM, Winkler\u00a0M, Engelmayer\u00a0S, Kugelmann\u00a0D, Egu\u00a0DT, Steinert\u00a0LS et\u00a0al (2023) Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus. Nat Commun 14(1):116","journal-title":"Nat Commun"},{"issue":"3","key":"5407_CR67","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1684\/ejd.2018.3280","volume":"28","author":"Y Waki","year":"2018","unstructured":"Waki\u00a0Y, Kamiya\u00a0K, Komine\u00a0M, Maekawa\u00a0T, Murata\u00a0S, Ishii\u00a0N et\u00a0al (2018) A\u00a0case of anti-laminin gamma1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast. Eur J Dermatol 28(3):413\u2013414","journal-title":"Eur J Dermatol"},{"issue":"11","key":"5407_CR68","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jid.2016.06.619","volume":"136","author":"H Koga","year":"2016","unstructured":"Koga\u00a0H, Recke\u00a0A, Vidarsson\u00a0G, Pas\u00a0HH, Jonkman\u00a0MF, Hashimoto\u00a0T et\u00a0al (2016) PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita. J\u00a0Invest Dermatol 136(11):2211\u20132220","journal-title":"J Invest Dermatol"},{"issue":"12","key":"5407_CR69","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamadermatol.2018.2191","volume":"154","author":"J Kieffer","year":"2018","unstructured":"Kieffer\u00a0J, Le Duff\u00a0F, Montaudie\u00a0H, Chiaverini\u00a0C, Lacour\u00a0JP, Passeron\u00a0T (2018) Treatment of Severe Hailey-Hailey Disease With Apremilast. JAMA Dermatol 154(12):1453\u20131456","journal-title":"JAMA Dermatol"},{"issue":"5","key":"5407_CR70","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/ced.14173","volume":"45","author":"A Di Altobrando","year":"2020","unstructured":"Di Altobrando\u00a0A, Sacchelli\u00a0L, Patrizi\u00a0A, Bardazzi\u00a0F (2020) Successful treatment of refractory Hailey-Hailey disease with apremilast. Clin Exp Dermatol 45(5):604\u2013605","journal-title":"Clin Exp Dermatol"},{"key":"5407_CR71","doi-asserted-by":"publisher","first-page":"884359","DOI":"10.3389\/fgene.2022.884359","volume":"13","author":"M Yamaga","year":"2022","unstructured":"Yamaga\u00a0M, Miyauchi\u00a0T, Peh\u00a0JT, Itamoto\u00a0S, Mai\u00a0Y, Iwata\u00a0H et\u00a0al (2022) Case report: Difference in outcomes between two cases of Hailey-Hailey disease treated with apremilast. Front Genet 13:884359","journal-title":"Front Genet"},{"issue":"2","key":"5407_CR72","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41401-021-00656-x","volume":"43","author":"QK Lu","year":"2022","unstructured":"Lu\u00a0QK, Fan\u00a0C, Xiang\u00a0CG, Wu\u00a0B, Lu\u00a0HM, Feng\u00a0CL et\u00a0al (2022) Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T\u00a0cells. Acta Pharmacol Sin 43(2):376\u2013386","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"5407_CR73","doi-asserted-by":"publisher","first-page":"166019","DOI":"10.1016\/j.bbadis.2020.166019","volume":"1867","author":"I Yougbare","year":"2021","unstructured":"Yougbare\u00a0I, Keravis\u00a0T, Lugnier\u00a0C (2021) NCS 613, a\u00a0PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL\/lpr lupus- prone mice. Biochim Biophys Acta Mol Basis Dis 1867(3):166019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"5407_CR74","doi-asserted-by":"publisher","first-page":"e28899","DOI":"10.1371\/journal.pone.0028899","volume":"7","author":"T Keravis","year":"2012","unstructured":"Keravis\u00a0T, Monneaux\u00a0F, Yougbare\u00a0I, Gazi\u00a0L, Bourguignon\u00a0JJ, Muller\u00a0S et\u00a0al (2012) Disease progression in MRL\/lpr lupus-prone mice is reduced by NCS 613, a\u00a0specific cyclic nucleotide phosphodiesterase type\u00a04 (PDE4) inhibitor. Plos One 7(1):e28899","journal-title":"Plos One"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05407-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05407-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:04:03Z","timestamp":1727791443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05407-7"}},"subtitle":["Die Rolle in der Behandlung von Hautkrankheiten","Role in the treatment of skin diseases"],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5407"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05407-7","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.F.\u00a0Schmidt, N.\u00a0Albuscheit und A.S.\u00a0Yazdi geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}